Reports have shown that Dll4 inhibition delays the tumor growth by deregulating the tumor angiogenic process [24–27], but in CRC anti-DLL4 therapy may also reduce the cancer stem cell frequency [29]. The gene discussed is DLL4; the disease is cancer.